



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1645

Applicant(s): Huang et al.

Serial No.: 10/615,809

Group Art Unit No.: 1645

Filed: July 8, 2003

Examiner: Not Yet Assigned

For: SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE

Docket No.: A-817

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form and provide(s) a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Joseph W. Bulock
 Attorney/Agent for Applicant(s)
 Registration No.: 37,103
 Phone: (805) 447-7966
 Date: October 29, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

10-29-2003

Date

Signature

Please send all future correspondence to:

US Patent Operations/JWB
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

Modified Form PTO-1449		Atty. Docket No. A-817	Serial No. 10/615.809
LIST OF REFERENCES CITED BY APPLICANT <i>Patent Office</i>		Applicant Huang et al.	
		Filing Date July 8, 2003	Group 1645
U.S. PATENT DOCUMENTS			

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	3,226,394	12/28/1965	Schipper			
	A2	5,532,358	7/2/1996	Kelly			
	A3	6,140,351	10/31/2000	Arnaiz et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
	B1	EP 0 947 500 A1	10/6/1999	Europe			
	B2	FR 2.168.227	01/21/1972	France			
	B3	JP 2000-256358	09/19/2000	Japan			
	B4	WO 96/41795	12/27/1996	PCT			
	B5	WO 98/24771	06/11/1998	PCT			
	B6	WO 98/45268	03/10/1998	PCT			
	B7	WO 99/32477	07/01/1999	PCT			
	B8	WO 99/62885	12/09/1999	PCT			
	B9	WO 00/02851	01/20/2000	PCT			
	B10	WO 00/27819	05/18/2000	PCT			
	B11	WO 00/27820	05/18/2000	PCT			
	B12	WO 00/39111	07/06/2000	PCT			
	B13	WO 00/39117	07/06/2000	PCT			
	B14	WO 01/29009 A1	04/26/2001	PCT			
	B15	WO 01/30745 A1	05/03/2001	PCT			
	B16	WO 01/55114 A1	08/02/2001	PCT			
	B17	WO 01/55115 A1	08/02/2001	PCT			
	B18	WO 01/81311 A1	11/01/2001	PCT			
	B19	WO 01/85671 A2	11/15/2001	PCT			
	B20	WO 01/85691 A1	11/15/2001	PCT			

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Modified Form PTO-1449		Atty. Docket No. A-817	Serial No. 10/615.809
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) NOV 03 2003 5C		Applicant Huang et al.	
		Filing Date July 8, 2003	Group 1645

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	MARK	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
		B21 WO 01/85715 A2	11/15/2001	PCT			
		B22 WO 02/46148 A1	06/13/2002	PCT			
		B23 WO 03/040101 A1	05/15/2003	PCT			

EXAMINER'S INITIALS OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

	C1	Breier et al., "The role of vascular endothelial growth factor in blood vessel formation", Trends in Cell Biology, 6:454-456 (1996).
	C2	Connell et al., "Patent focus on cancer chemotherapeutics. II Angiogenesis agents: April 2000 – September 2000", Expert Opinion on Therapeutic Patents, 11(1):77-114 (2001).
	C3	Konshin et al., "Synthesis and antimicrobial activity of aryl-amides of N-(4-pyridyl)anthranilic acid", Chemical Abstracts, 97:109837g, pg. 596 (1982).
	C4	Seto et al., "Molecular Self-Assembly through Hydrogen Bonding: Supramolecular Aggregates Based on the Cyanuric Acid-Melamine Lattice", Journal of the American Chemical Society, 115:905-916 (1993).
	C5	Singh et al., "Substituted Imidazolines and their CNS Activity", Indian Journal of Heterocyclic Chemistry, 2:129-132 (1992).

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	